Home / Market News / $IGC

$IGC news and market catalysts

The 6 most recent market catalysts affecting $IGC, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

6 catalysts 0 high impact 4 bullish 1 bearish Pharmaceuticals
Nov 18, 2026 Corporate Catalyst Bullish Impact 65
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1
IGC Pharma has completed patient dosing in its Phase 2 CALMA trial for IGC-AD1, a cannabinoid-based formulation targeting agitation in Alzheimer's dementia. This milestone signifie…
Nov 9, 2026 Corporate Catalyst Neutral Impact 75
IGC Pharma Reports Third Quarter 2026 Financial Results and Provides Business Update
IGC Pharma has completed enrollment for its CALMA clinical trial, a crucial step for any pharmaceutical company. This signifies progress towards potential market approval for IGC-A…
Nov 6, 2026 Corporate Catalyst Bullish Impact 65
IGC Pharma Receives Canadian Patent for Alzheimer's Agitation Drug Candidate IGC-AD1
IGC Pharma has successfully obtained a Canadian patent for IGC-AD1, its lead drug candidate for Alzheimer's agitation. This is significant because it finalizes intellectual propert…
Sep 28, 2026 Corporate Catalyst Bullish Impact 65
IGC Pharma Announces Completion Of 168-Patient Enrollment In Phase 2 Trial Of IGC-AD1 For Alzheimer's Agitation; Topline Data Expected Q4 2026
The completion of patient enrollment for a Phase 2 trial is a crucial de-risking event for any pharmaceutical company, especially in a challenging area like Alzheimer's. This news …
Aug 26, 2026 Corporate Catalyst Bullish Impact 55
Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $6
Ascendiant Capital analyst Edward Woo maintained a 'Buy' rating on IGC Pharma and raised the price target from $5.50 to $6. This analyst upgrade signals increased confidence in IGC…
Aug 17, 2026 Corporate Catalyst Bearish Impact 75
IGC Pharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $265.000K Beat $258.000K Estimate
IGC Pharma's Q2 results show a mixed performance. While the company missed EPS estimates significantly and saw a larger loss compared to the previous year, it also managed to beat …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.